Immune Inc.

NCT00346385

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00352131

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

NCT00346255

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

NCT00721669

A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

NCT00755703

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT00991562

IMGN901 in Combination With Lenalidomide and Dexamethasone

NCT01534715

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

NCT01609556

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

NCT01963715

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

NCT02496897

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

NCT02528799

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

NCT02674763

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

NCT03383952

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

NCT03383965

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

NCT03102320

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

NCT03352466

NasoShield Study of Safety and Immunogenicity

NCT03543540

Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease

NCT03552471

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03653208

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

NCT04415749

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04817202

Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

NCT04561245

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NCT04679909

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

NCT04972396

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

NCT05006885

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05134662

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05292911

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

NCT05429021

IMM-BCP-01 in Mild to Moderate COVID-19

NCT06372652

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

NCT06677996

A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants

NCT06855264

A Cardiac Liability Study of Varegacestat in Healthy Participants

NCT06845852

A Phase 1 Mass Balance Study of Varegacestat

NCT06823167

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06841315

A Varegacestat Hepatic Impairment Study